150 related articles for article (PubMed ID: 34959847)
1. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study.
Keizman D; Frenkel M; Peer A; Kushnir I; Rosenbaum E; Sarid D; Leibovitch I; Mano R; Yossepowitch O; Margel D; Wolf I; Geva R; Dresler H; Rouvinov K; Rapoport N; Eliaz I
Nutrients; 2021 Nov; 13(12):. PubMed ID: 34959847
[TBL] [Abstract][Full Text] [Related]
2. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study.
Keizman D; Frenkel M; Peer A; Rosenbaum E; Sarid D; Leibovitch I; Mano R; Yossepowitch O; Wolf I; Geva R; Margel D; Rouvinov K; Stern A; Dresler H; Kushnir I; Eliaz I
Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630724
[TBL] [Abstract][Full Text] [Related]
3. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.
Guess BW; Scholz MC; Strum SB; Lam RY; Johnson HJ; Jennrich RI
Prostate Cancer Prostatic Dis; 2003; 6(4):301-4. PubMed ID: 14663471
[TBL] [Abstract][Full Text] [Related]
4. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Liu G; Chen YH; Kolesar J; Huang W; Dipaola R; Pins M; Carducci M; Stein M; Bubley GJ; Wilding G
Urol Oncol; 2013 Feb; 31(2):211-8. PubMed ID: 21784672
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.
Clark PE; Hall MC; Borden LS; Miller AA; Hu JJ; Lee WR; Stindt D; D'Agostino R; Lovato J; Harmon M; Torti FM
Urology; 2006 Jun; 67(6):1257-61. PubMed ID: 16765186
[TBL] [Abstract][Full Text] [Related]
6. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.
Paller CJ; Rudek MA; Zhou XC; Wagner WD; Hudson TS; Anders N; Hammers HJ; Dowling D; King S; Antonarakis ES; Drake CG; Eisenberger MA; Denmeade SR; Rosner GL; Carducci MA
Prostate; 2015 Oct; 75(14):1518-25. PubMed ID: 26012728
[TBL] [Abstract][Full Text] [Related]
9. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.
Lee M; Hong H; Kim W; Zhang L; Friedlander TW; Fong L; Lin AM; Small EJ; Wei XX; Rodvelt TJ; Miralda B; Stocksdale B; Ryan CJ; Aggarwal R
Clin Genitourin Cancer; 2019 Feb; 17(1):e92-e96. PubMed ID: 30327180
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride monotherapy in men with serologic relapse following radical therapy for adenocarcinoma of the prostate: a pilot study.
Perrotti M; Jain R; Abriel LM; Baroni TE; Corbett AB; Tenenbaum SA
Urol Oncol; 2012; 30(2):133-8. PubMed ID: 20800512
[TBL] [Abstract][Full Text] [Related]
11. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.
Paller CJ; Olatoye D; Xie S; Zhou X; Denmeade SR; Eisenberger MA; Antonarakis ES; Carducci MA; Rosner GL
Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):28-33. PubMed ID: 24100642
[TBL] [Abstract][Full Text] [Related]
12. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Cheung E; Pinski J; Dorff T; Groshen S; Quinn DI; Reynolds CP; Maurer BJ; Lara PN; Tsao-Wei DD; Twardowski P; Chatta G; McNamara M; Gandara DR
Clin Genitourin Cancer; 2009 Jan; 7(1):43-50. PubMed ID: 19213668
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin.
Pienta KJ; Naik H; Akhtar A; Yamazaki K; Replogle TS; Lehr J; Donat TL; Tait L; Hogan V; Raz A
J Natl Cancer Inst; 1995 Mar; 87(5):348-53. PubMed ID: 7853416
[TBL] [Abstract][Full Text] [Related]
14. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Antonarakis ES; Zahurak ML; Lin J; Keizman D; Carducci MA; Eisenberger MA
Cancer; 2012 Mar; 118(6):1533-42. PubMed ID: 21960118
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
Lin AM; Rini BI; Weinberg V; Fong K; Ryan CJ; Rosenberg JE; Fong L; Small EJ
BJU Int; 2006 Oct; 98(4):763-9. PubMed ID: 16796694
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
17. Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.
Calcagno F; Mouillet G; Adotevi O; Maurina T; Nguyen T; Montcuquet P; Curtit E; Kleinclauss F; Pivot X; Borg C; Thiery-Vuillemin A
Med Oncol; 2016 Aug; 33(8):89. PubMed ID: 27400698
[TBL] [Abstract][Full Text] [Related]
18. Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.
McLaren DB; McKenzie M; Duncan G; Pickles T
Cancer; 1998 Jan; 82(2):342-8. PubMed ID: 9445192
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer.
Pantuck AJ; Pettaway CA; Dreicer R; Corman J; Katz A; Ho A; Aronson W; Clark W; Simmons G; Heber D
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):242-8. PubMed ID: 26169045
[TBL] [Abstract][Full Text] [Related]
20. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
